Danaher (DHR) Tops Q4 EPS by 25c, Revenues Beat

Danaher (NYSE: DHR) reported Q4 EPS of $2.08, $0.25 better than the analyst estimate of $1.83. Revenue for the quarter came in at $6.8 billion versus the consensus estimate of $6.44 billion.

Rainer M. Blair, President and Chief Executive Officer, stated, "For the full year 2020, we achieved nearly 10% core revenue growth including Cytiva, strong margin expansion, and more than $5 billion of free cash flow. But our financial results only tell part of the story. Despite many unforeseen challenges as a result of the COVID-19 pandemic, our team turned the challenges we faced into impactful opportunities to support our customers and the global community. We're proud to play a pivotal role in the fight against COVID-19, and our 2020 results are a testament to our team's commitment and perseverance."

Blair added, "2020 was also a transformative year for Danaher with the addition of Cytiva—the largest acquisition in our Company's history and one that has strengthened our position as a global science and technology leader. Going forward, we believe the combination of our portfolio, innovative team, and strong balance sheet—all powered by the Danaher Business System—positions us to deliver sustainable, long-term shareholder value for many years to come."

For earnings history and earnings-related data on Danaher (DHR) click here.

You May Also Be Interested In

• Growth isn't weak enough to truly undercut inflation pressures - BMO
• Park National Corp. (PRK) Tops Q1 EPS by 36c
• Progress Software Corporation (PRGS) Issues Statement on a Possible Offer for MariaDB